Alexandra Thomas, MD, FACP
- Professor, Hematology and Oncology

Alexandra Thomas, MD, FACP
- Education
- AB, Princeton University, 1987
- MD, Johns Hopkins University School of Medicine, 1995
- Residency
- Internal Medicine, Stanford University School of Medicine, 1998
- Fellowship
- Medical Oncology, University of Iowa College of Medicine, 2008
- Board Certifications
- American Board of Internal Medicine, Medical Oncology
- Positions
- Williams Family Professorship in Breast Oncology
Professor, Hematology and Oncology - Departments and Affiliations
- Hematology and Oncology
- Comprehensive Cancer Center
Research
- Incidence and Survival Among Young Women With Stage I-III Breast Cancer: SEER 2000-2015. Thomas A, Rhoads A, Pinkerton E, Schroeder MC, Conway KM, Hundley WG, McNally LR, Oleson J, Lynch CF, Romitti PA. . 2019 Sep; 3(3):pkz040.
- Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF. Sharma S, Wu SY, Jimenez H, Xing F, Zhu D, Liu Y, Wu K, Tyagi A, Zhao D, Lo HW, Metheny-Barlow L, Sun P, Bourland JD, Chan MD, Thomas A, Barbault A, D'Agostino RB, Whitlow CT, Kirchner V, Blackman C, Pasche B, Watabe K. EBioMedicine. 2019 Jun; 44:194-208.
- Frequency of Transition From Stage A to Stage B Heart Failure After Initiating Potentially Cardiotoxic Chemotherapy. Jones DN, Jordan JH, Meléndez GC, Lamar Z, Thomas A, Kitzman DW, Suerken C, D'Agostino RB, Hundley WG. JACC Heart Fail. 2018 12; 6(12):1023-1032.
- Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. Furqan M, Tien YY, Schroeder MC, Parekh KR, Keech J, Allen BG, Thomas A, Zhang J, Clamon G, Abu Hejleh T. J Thorac Dis. 2018 Oct; 10(10):5850-5859.
- Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Samykutty A, Grizzle WE, Fouts BL, McNally MW, Chuong P, Thomas A, Chiba A, Otali D, Woloszynska A, Said N, Frederick PJ, Jasinski J, Liu J, McNally LR. Biomaterials. 2018 11; 182:114-126.
- I-SPY 2 Trial: Study of multiple drugs and imaging techniques to predict treatment responses in Breast Cancer
- A study of the drug Trastuzumab Deruxtecan (T-DXd) compared to the drug Trastuzumab Emtansine (T-DM1) in Individuals with HER2-Positive Primary Breast Cancer
- Learning How Certain Medications May Modify the Gut Microbiome (Bacteria in the Gut) among Individuals with Breast Cancer